Darolutamide Now Approved as Single Agent for MCSPC ...Middle East

Medscape - News
Darolutamide Now Approved as Single Agent for MCSPC
The FDA approval is based on safety and efficacy demonstrated in the phase 3 ARANOTE trial, which evaluated darolutamide — without docetaxel chemotherapy — vs placebo. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Darolutamide Now Approved as Single Agent for MCSPC )

Also on site :